Social Media Ideas for Day One Biopharmaceuticals

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO - Slideshow

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

A Spanish biotech banks $87M to make differentiated ADCs

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA...

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...

Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

Parabilis Files for IPO, a Day After Signing Up-to-$2.3B Regeneron Collaboration

The company’s IPO filing came a day after Parabilis inked an up-to-$2.3 billion-plus strategic research collaboration with Regeneron Pharmaceuticals to discover and develop an init...

<![CDATA[Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ]]>

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Major Biopharmaceutical Company Files First-in-Human Trial Supported by PAK BioSolutions GMP Purification System

A major biopharmaceutical company has filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system. The milestone demons...

<![CDATA[Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301]]>

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon fol...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Datroway]]>

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Col...

BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug

A BioMarin Pharmaceutical drug met just one of two main goals of a Phase 3 test in a rare inherited enzyme deficiency with no FDA-approved therapies. The drug, a fusion protein, ca...

Inflammation Startup Bionyra Launches With $165M and Ex-Sanofi Exec at the Helm

Bionyra Pharma’s pipeline includes two drugs that target the signaling protein TL1A, alone and as part of a combination approach to treat inflammatory disorders. The startup’s laun...

Bionyra brings in $165M for next-generation immune drugs

The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.